ストックスクリーナーアプリを入手
23.75
1.08%
-0.26
アフターアワーズ：
23.67
-0.08
-0.34%
Hims Hers Health Inc (HIMS) 最新ニュース
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
Four telehealth platforms now offer generic semaglutide - Benefits and Pensions Monitor
Hims & Hers Health stock price forecast: $22.50 support as HIMS trades down - Traders Union
(HIMS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Hims & Hers Health (HIMS) Stock Forum and Discussion - Moomoo
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Health Options Spot-On: On May 22nd, 109.56K Contracts Were Traded, With 1.05 Million Open Interest - Moomoo
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer - Stock Titan
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees - Stock Titan
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees - Stock Titan
Latham Advises on Hims & Hers Health, Inc.’s Upsized US$350 Million Convertible Senior Notes Offering - Latham & Watkins LLP
HIMS Maintained by Truist Securities -- Price Target Raised to $23 - GuruFocus
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
Hims & Hers Has Fallen 66% From Its Peak. Does the $350M Debt Raise Signal a Turning Point or a Red Flag? - TIKR.com
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Hims & Hers launches generics for Novo’s semaglutide in Canada - Seeking Alpha
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - HIMS Investor Relations
Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers - Hims & Hers Newsroom
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
HIMS Stock Midweek Analysis | Hims & Hers Health, Inc. (HIMS) Stock Forecast (IK4SVsTRUr) - fathomjournal.org
Hims & Hers Health Q1 2026: Strategic Shift to Branded Medications Weighs on Results - IndexBox
Eucalyptus acquisition prospect lifts Hims & Hers Health stock 2.67% higher - Traders Union
HIMS Becomes a Retail Sentiment Standout as Bullish Mentions Rise to 70% - openPR.com
HIMS Stock Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
Live Longer and Better. Does Medicine’s New Obsession Really Work? - Barron's
Hims & Hers Health, Inc. - dailyvoice.com
Hims & Hers stock slips as dilution fears outweigh new capital - MSN
Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital - Benzinga
Hims & Hers: Wegovy Deal Fuels Growth (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Swings to First-Quarter Loss as Weight-Loss Pivot Drives Up Costs - WSJ
Barclays Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $29 - Moomoo
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call - Yahoo Finance
Hims & Hers Health, Inc.: Shareholders Board Members Managers and Company Profile | AR0162508391 - marketscreener.com
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1 - Yahoo Finance
Hims & Hers (HIMS) CFO sells 7,950 shares after option exercise - Stock Titan
HIMS Maintained by B of A Securities -- Price Target Lowered to $28 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health Options Spot-On: On May 19th, 113.05K Contracts Were Traded, With 982.6K Open Interest - Moomoo
Why is Hims & Hers stock being hammered today? By Investing.com - Investing.com Nigeria
Is CAH Becoming the Backbone of US Healthcare Infrastructure? - TradingView
Hims & Hers Massive Stock Drop Explained - The Motley Fool
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):